Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 2/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | GNRHR | P30968 | 12/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL8554402 | 0.85 | NPY1R (0.43) | NPY1RGNRHRDGAT2LTA4H | |
| SCHEMBL8554215 | 0.80 | NPY1R (0.49) | NPY1RDGAT2 | |
| Trifluoroacetic Acid SCHEMBL8553079 | 0.79 | NPC1 (0.38) | GNRHR | |
| Trifluoroacetic Acid SCHEMBL8552705 | 0.79 | NPY1R (0.38) | NPY1RDGAT2 | |
| Trifluoroacetic Acid SCHEMBL8552526 | 0.79 | NPY1R (0.41) | NPY1RDGAT2 | |
| SCHEMBL8551098 | 0.78 | RAB9A (0.45) | DGAT2 | |
| Trifluoroacetic Acid SCHEMBL8555259 | 0.78 | RHEB (0.38) | NPY1RDGAT2 | |
| Trifluoroacetic Acid SCHEMBL8555314 | 0.78 | NPY1R (0.45) | NPY1RHRH4 | |
| SCHEMBL8553502 | 0.77 | NPY1R (0.48) | NPY1RDGAT2 | |
| SCHEMBL8554433 | 0.77 | NPY1R (0.47) | NPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0871442-A1 | BENZIMIDZOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1998-10-21 | — | — | EP | disclosed |
| WO-1997025041-A1 | BENZIMIDZOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-07-17 | — | — | WO | disclosed |